1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Medtronic Sponsors ALLEVIATE HF Remote Heart Failure Monitor

 
• By Reed Miller

The randomized trial will evaluate the ability of the Reveal LINQ insertable monitor to help physicians prevent the progression of heart failure.

Heart Failure - Printed Diagnosis with Red Pills, Injections and Syringe. Medical Concept with Selective Focus.
• Source: shutterstock.com

Medtronic plc is sponsoring a randomized trial to evaluate the ability of a new algorithm for the Reveal LINQ insertable cardiac monitor to identify patients at high risk of worsening heart failure.

Reveal LINQ is a monitor about one-third the size of a AAA battery that is inserted just beneath the skin...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

With CMS Coverage Established, Medtronic Looks To Next Steps For Renal Denervation

 
• By Elizabeth Orr

US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 
• By Natasha Barrow

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 
• By Brian Bossetta

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 
• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

More from R&D